DOCSLIB.ORG

Vernalis Plc Vernalis ANNUAL REPORT and ACCOUNTS 2015/16

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vernalis Plc Vernalis ANNUAL REPORT and ACCOUNTS 2015/16 Vernalis plc Vernalis ANNUAL REPORT AND ACCOUNTS 2015/16 Vernalis plc ANNUAL REPORT AND ACCOUNTS 2015/16 Vernalis plc Annual report and accounts 2015/16 Overview Who we are Vernalis is a commercial stage Our business model balances risk pharmaceutical company with and innovation, with the aim of three marketed products; Tuzistra® XR creating value through a focused in the US prescription cough cold and disciplined three-tier strategy: market, Moxatag® the only once- daily amoxicillin approved in the Building a profitable and cash- US for tonsillitis and pharyngitis, and generative business by developing and commercialising low development-risk, frovatriptan an acute treatment for late-stage differentiated pharmaceutical migraine. The Company also has products for unmet medical needs. four further prescription cough cold Partnering our NCE drug candidates, products under development with earning milestones and royalties as Tris and a broad pipeline of NCE partners progress them to the market. development programmes and Leveraging our fragment- and structure- based drug discovery expertise and proven research collaborations. record of success to enter into revenue generating collaborations with larger pharmaceutical companies with potential to receive milestone payments and royalties. Overview Directors’ report Financial statements 01 2015/16 at a glance 26 Board of directors 49 Independent auditors’ report 02 Chairman’s and Chief Executive 28 Directors’ report 51 Consolidated income statement Officer’s statement 51 Consolidated statement of Corporate governance comprehensive income Strategic report 32 Corporate governance 52 Balance sheets 04 Our strategy and business model 37 Remuneration report 53 Statements of changes in equity 06 Business review 48 Statement of directors’ responsibilities 54 Cash flow statements 18 Financial review 55 Notes to the financial statements 22 Principal risks and uncertainties Additional information 91 Shareholder information 92 Glossary of abbreviations/definitions ibc Addresses and advisers Vernalis plc Annual report and accounts 2015/16 Annual report and accounts 2015/16 Vernalis plc Vernalis plc Annual report and accounts 2015/16 Annual report and accounts 2015/16 Vernalis plc Vernalis plc Annual report and accounts 2015/16 Annual report and accounts 2015/16 Vernalis plc Overview Corporate governance Overview Corporate governance Overview Corporate governance Overview Corporate governance Overview Corporate governance Overview Corporate governance 08 Strategic report Financial statements Strategic report Financial statements 09 10 Strategic report Financial statements Strategic report Financial statements 11 12 Strategic report Financial statements Strategic report Financial statements 13 Directors’ report Additional information Directors’ report Additional information Directors’ report Additional information Directors’ report Additional information Directors’ report Additional information Directors’ report Additional information Business review Business review Business review COMMERCIAL PIPELINE COMMERCIAL PIPELINE COMMERCIAL PIPELINE CONTINUED 2015/16 TUZISTRA® XR LAUNCH GOALS CONTINUED CONTINUED Recognising that our evolution to a full their prescription fi lled. These programmes commercial stage company would are working well and we continue to trigger signifi cant operational changes monitor the level of benefi t provided to THE FACE THE FACE THE FACE THE FACE to what had been a development stage ensure Tuzistra® XR remains affordable. company, we set ourselves realistic goals Supply • Routine supply from Tris ® OF VERNALIS OF VERNALIS OF VERNALIS OF VERNALIS for Tuzistra XR’s fi rst year on the market. The fi nal area of focus for 2015/16 was • Routine 3PL operations ® These include goals across: supply chain; to establish our fi eld sales force and to Sandy Sommer* Jillian Armenti* Dr Louis J Citarelli, MD* Tuzistra XR patient* trade distribution; patient access and begin building awareness of Tuzistra® President and Chief Operating Professional Sales Physician/Internal Medicine, Mary, NJ affordability; and sales force effectiveness. XR with high cough cold prescribing Trade • Wholesaler contracts physicians. Our expectations for our Offi cer, VTI Representative, Orange, NJ Nutley, NJ distribution • In supply chain, the 2015/16 focus was fi rst year were very modest, recognising National distribution to establish routine supply from Tris and that the sales representatives were new • Pharmacy stocking Ongoing warehousing and distribution at our 3PL and did not have existing familiarity partner. Both of these were completed or relationships with our target in early summer 2015 and have been physicians. In addition, Tuzistra® XR is • Tier 3 non-restricted coverage Ongoing fully operational for the whole of the a new brand with which neither the Patient year. Our fi rst year commercial goals sales representatives nor physicians access • Patient access coupon for trade distribution were to establish are familiar. Performance in the fi rst 12 national wholesale distribution and months since launch was modest with widespread pharmacy stocking. Although approximately 12,000 prescriptions fi lled. we achieved our wholesale distribution SUPPORTED BY PHYSICIAN MARKET goals with 15 customers holding Our goals for the approaching cough Brand • Establish fi eld force RESEARCH FROM CODEINE AND our inventory in over 70 distribution cold season are to secure wider formulary awareness • Field force effectiveness Ongoing centres, achieving pharmacy stocking coverage and pharmacy distribution HYDROCODONE PRESCRIBERS and usage • Build brand awareness Ongoing has been much slower than we had and to build sales force effectiveness INDICATING SIGNIFICANT hoped. This has limited early Tuzistra® XR within our target physician audience • Grow prescriptions Ongoing POTENTIAL USAGE AND MARKET prescriptions because physicians are less whilst maintaining patient affordability. SHARE likely to prescribe until stocking is more We will monitor performance against widespread. We estimate that ~25 per these goals which, if achieved, will cent of prescriptions written by physicians position us favourably for accelerated are abandoned by patients, some of growth in prescription volume in the TUZISTRA® XR US PRESCRIPTION COUGH COLD MARKET which is due to lack of pharmacy stocking. 2016/17 cough cold season. MAT June 2016 ONE DOSE A DAY MAT June MAT June MAT June MAT June MAT June • Our fi rst year patient access and Moxatag® 2011 TRx m 2012 TRx m 2013 TRx m 2014 TRx m 2015 TRx m TRx m % vs 2011 % • INDICATED FOR THE TREATMENT affordability goals focused on establishing The US rights to Moxatag®, a once-daily Narcotics 19.1 17.0 19.0 16.3 16.1 14.1 42 (26) OF TONSILLITIS AND/OR formulary coverage under commercial formulation of amoxicillin, were acquired Codeine 13.3 11.7 13.2 11.4 12.4 11.1 33 (16) PHARYNGITIS SECONDARY TO healthcare insurance plans and in October 2015, to expand our primary +Antihistamines 5.6 4.9 5.3 4.6 4.7 4.3 13 (22) STREPTOCOCCUS PYOGENES providing patients with co-pay assistance care product portfolio and leverage +Expectorants 6.8 6.0 7.1 6.2 7. 2 6.4 19 (5) FOR ADULTS AND PAEDIATRIC programmes to make their out-of-pocket our US commercial infrastructure. +Others 0.9 0.8 0.8 0.6 0.5 0.4 1 (59) • costs affordable. We anticipate that it will PATIENTS (12 YEARS OF AGE take 24 months to achieve our formulary Following the acquisition, we successfully Hydrocodone 5.8 5.3 5.8 4.9 3.7 3.0 9 (48) OR OLDER) coverage goals of unrestricted tier-3 re-established product supply from +Antihistamines 2.7 2.5 2.7 2.3 1.7 1.4 4 (49) coverage on formularies covering 75 per its FDA approved manufacturing +Anticholinergics 2.9 2.5 2.8 2.5 1.9 1.6 5 (44) +Others 0.2 0.3 0.3 0.1 0.1 0.0 0 (96) cent of commercial lives. We made good partner, Suir, in March 2016. ® ® progress in 2015/16 with ~60 per cent of “ As the President and COO of Vernalis Therapeutics, Inc., I am in the privileged “ I am a Sales Representative for VTI and work within the Northeast region in “ I recommend Tuzistra XR to my patients when they are suffering with cough “ I was prescribed Tuzistra XR about a month ago. Before that I had tried various Non-narcotics 16.2 12.4 15.2 15.2 18.6 19.4 58 20 ® commercial lives covered with unrestricted In May 2016, Suir entered liquidation and position of leading the US organisation through an exciting period of growth. the Orange, New Jersey territory. I speak to Healthcare Practitioners (HCPs) and cold symptoms because one dose every 12 hours provides extended treatments but nothing stopped my cough. Tuzistra XR made me feel so much access. However, there are notable so activities are underway to establish Dextromethorphan 9.7 6.3 7.3 7.2 8.9 8.9 27 (8) We have a unique portfolio of cough and cold medications that offer patients about prescribing Tuzistra® XR to provide extended-relief to patients suffering cough relief. I have a good working relationship with Jillian Armenti, my local better and it allowed me to fi nally get on with my life without coughing.” gaps which, together with maintaining and qualify an alternative manufacturing +Antihistamines 2.6 2.7 3.5 3.4 4.2 4.4 13 68 a distinct dosing advantage over what is currently available today. With the from cough and symptoms of the common cold or upper respiratory allergies Vernalis Therapeutics representative, whom I fi nd knowledgeable about the coverage already achieved, will be site for ongoing supply of the product. Triple-combinations 7.1 3.6 3.8 3.8 4.7 4.5 13 (36) talented team we have in place, coupled with a rapidly expanding portfolio while ensuring pharmacies have the product on-shelf for patients to get Tuzistra® XR and helpful in addressing any access concerns.” priorities for 2016/17. During 2015/16 ® we have made available two parallel The product will be relaunched into the Benzonatate 5.7 5.9 7.8 7.9 9.4 10.3 31 81 of approved products, we are poised to become one of the leading cough on treatment right away.
Load more

Recommended publications
  • Chief Executive Officer Graham Baker
    OVERVIEW OUR BUSINESS OPERATIONAL FINANCIAL RISK GOVERNANCE ACCOUNTS 48 & MARKETPLACE REVIEW REVIEW OUR BOARD OF DIRECTORS ROBERTO QUARTA (67) OLIVIER BOHUON (58) GRAHAM BAKER (48) CHAIRMAN CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Joined the Board in December 2013 and Joined the Board and was appointed Chief -RLQLQJWKH%RDUGDV&KLHI)LQDQFLDO2I²FHULQ appointed Chairman following election by ([HFXWLYH2I²FHULQ$SULO+HUHVLJQHGDV March 2017. shareholders at the April 2014 Annual General a Member of the Nomination & Governance Meeting. He was also appointed Chairman of &RPPLWWHHRQ)HEUXDU\ CAREER AND EXPERIENCE the Nomination & Governance Committee and Graham holds an MA degree in Economics from a Member of the Remuneration Committee on CAREER AND EXPERIENCE Cambridge University and qualified as a Chartered that day. Olivier holds a doctorate in Pharmacy from the Accountant and Chartered Tax Advisor with Arthur University of Paris and an MBA from HEC, Paris. Andersen. In 1995, he joined AstraZeneca PLC where CAREER AND EXPERIENCE He started his career in Morocco with Roussel Uclaf he worked for 20 years, holding multiple senior roles, Roberto is a graduate and a former Trustee of the S.A. and then, with the same company, held a number including Vice President, Finance, International (2013- College of the Holy Cross, Worcester (MA), US. of positions in the Middle East with increasing levels of 2015) with responsibility for all emerging markets, He started his career as a manager trainee at David responsibility. He joined Abbott in Chicago as head of Vice President, Global Financial Services (2011-2013) Gessner Ltd, before moving on to Worcester Controls their anti-infective franchise with Abbott International and Vice President Finance & Chief Financial Officer, Corporation and then BTR plc, where he was a before becoming Pharmaceutical General Manager North America (2008-10).
    [Show full text]
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Form 8-K Ligand Pharmaceuticals
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2020 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 (Address of principal executive offices) (Zip Code) (858) 550-7500 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • Milner Symposium 2020
    THERAPEUTICS SYMPOSIUM 2020 GLOBAL THERAPEUTIC ALLIANCE OVERVIEW A SERIES OF ONLINE EVENTS STARTING ON JUNE 12TH ALLIANCE GLOBAL THERAPEUTIC ALLIANCE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration. GLOBAL THERAPEUTIC ALLIANCE Research in the Milner Therapeutics Institute is funded by: Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p4), and the Alliance has been expanded with the Affiliated Company p8( ) and Affiliated Institutions scheme p37( ) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge. The Affiliated Venture Partnersprogramme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon. 3 CONSORTIUM ASTEX PHARMACEUTICALS MILNER THERAPEUTICS CONSORTIUM The Milner Therapeutics Astex is a leader in innovative drug discovery and Consortium is an academic- development, committed to the fight against cancer and industry partnership, active since diseases of the central nervous system. Astex is developing June 2015. This is underpinned a proprietary pipeline of novel therapies and has multiple
    [Show full text]
  • 1999 Annual Report and Form 20-F CONTENTS
    1999 Annual Report and Form 20-F CONTENTS Key Achievements in 1999 1 Financial Highlights 2 Shareholder Highlights 5 Chairman’s Statement 6 Chief Executive’s Review 7 Operational Review 8 Safety, Health and Environment 32 In April 1999, Astra AB and Zeneca Group PLC People and Community 34 merged to form AstraZeneca, one of the world’s Financial Review 35 leading pharmaceutical and agrochemical Board of Directors and Officers companies, which provides innovative, effective of the Company 48 products to improve health, nutrition and quality Directors’ Report 49 of life worldwide. The company is research and Financial Statements 55 technology intensive, with extensive international Financial statements and notes development and marketing skills. Its healthcare relating to the financial statements 55 business is strategically focused on seven major Principal subsidiaries, joint ventures therapeutic areas: gastrointestinal, oncology, pain and associates 118 control and anaesthesia, cardiovascular, central Additional information for US investors 120 nervous system, respiratory and infection. Zeneca Group Financial Record 129 Agrochemicals provides crop protection products Shareholder Information 131 designed to improve crop yields and food quality. Exchange rates 138 Definitions 139 Glossary of Terms 140 Cross Reference to Form 20-F IBC Cautionary statement regarding forward-looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Annual Report and Form 20-F 1999 contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future.
    [Show full text]
  • Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
    www.nature.com/npjprecisiononcology ARTICLE OPEN Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy Gonzalo Recondo 1, Linda Mahjoubi2, Aline Maillard3, Yohann Loriot1,4, Ludovic Bigot1, Francesco Facchinetti1, Rastislav Bahleda2, Anas Gazzah2, Antoine Hollebecque2, Laura Mezquita4, David Planchard1,4, Charles Naltet4, Pernelle Lavaud4, Ludovic Lacroix1,5,6, Catherine Richon5, Aurelie Abou Lovergne7, Thierry De Baere8, Lambros Tselikas8, Olivier Deas9, Claudio Nicotra2, Maud Ngo-Camus2, Rosa L. Frias1, Eric Solary10, Eric Angevin2, Alexander Eggermont4, Ken A. Olaussen1, Gilles Vassal7, Stefan Michiels 3, ✉ Fabrice Andre 1,4, Jean-Yves Scoazec5,6, Christophe Massard1,2, Jean-Charles Soria1,4, Benjamin Besse1,4 and Luc Friboulet 1 Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole 1234567890():,; exome sequencing.
    [Show full text]
  • 4586728.98 in 2005
    Detail Awards by Sponsor Dept Name FY05 Award Federal National Cancer Institute 47,048,096.55 National Institute of Heart, Lung, and Blood 38,794,591.33 National Institute of General Medicine Science 30,400,147.18 National Institute of Child Health & Human Development 29,863,697.92 National Institute of Allergy & Infectious Diseases 27,492,973.12 National Science Foundation - Research 20,659,748.00 National Institute of Diabetes, Digestive & Kidney Diseases 19,575,845.00 National Center for Research Resources 19,179,710.00 National Institute of Mental Health-NIH 16,727,938.80 US Department of Education 15,868,100.00 US Agency for International Development 12,743,904.00 National Institute of Environmental Health Sciences 11,961,787.00 National Institute of Neurologic Disorders and Stroke 11,957,697.00 Centers for Disease Control 10,507,132.00 National Institute of Dental and Craniofacial Research 7,032,009.35 National Institute on Alcohol Abuse & Alcoholism 6,874,910.00 Bureau of Health Professions 5,797,479.00 National Institute of Arthritis Musculoskeletal Skin Disease 4,921,205.00 US Environmental Protection Agency - GRANTS 4,586,728.98 National Institute on Aging 4,159,889.94 National Institute on Drug Abuse 4,111,248.00 National Institute of Nursing Research 4,094,244.00 National Institute of Biomedical Imaging and Bioengineering 4,079,842.59 Maternal and Child Health Bureau 4,049,730.00 National Science Foundation - Training 3,877,378.00 National Center for Chronic Disease Prev & Health Promo(CDC) 3,384,180.00 US Department of Defense
    [Show full text]
  • Disclosure of Financial Relationships April 10-15 • May 17-21
    DISCLOSURE OF FINANCIAL RELATIONSHIPS APRIL 10-15 • MAY 17-21 In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has pro- vided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Share- holder, SB, Speakers’ Bureau, H, Honoraria, O, Other. Last Name First Name Company Relationships Type Role Abate-Shen Cory NY Presbyterian Hospital Herbert Irving Comp. No Relationships Speaker Cancer Center Abdulkadir Sarki Northwestern University No Relationships Speaker Acharyya Swarnali Columbia University No Relationships Speaker Achilefu Samuel Washington University School of Medicine Sarya LLC; Integro Theranostics LLC C,O Speaker Adalsteinsson Viktor Broad Institute of MIT and Harvard Bertis Inc; AGCT GMBH A Speaker Adamopoulos Christos Icahn School of Medicine at Mount Sinai No Relationships Speaker Adamson Peter Sanofi Sanofi; AbbVie; Gilead; McKesson E,S Program Committee Agrawal Sundeep
    [Show full text]